Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SHE:301093)
127.15
+1.15 (0.91%)
At close: May 28, 2026
SHE:301093 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 600.02 | 616.04 | 584.45 | 621.9 | 583.67 | 819.27 |
Other Revenue | 3.41 | 3.41 | 1.96 | 1.03 | 0.47 | 1.6 |
| 603.43 | 619.45 | 586.41 | 622.92 | 584.14 | 820.87 | |
Revenue Growth (YoY) | -0.33% | 5.63% | -5.86% | 6.64% | -28.84% | 83.92% |
Cost of Revenue | 372.6 | 382 | 363.66 | 367.57 | 334.13 | 373.85 |
Gross Profit | 230.83 | 237.46 | 222.76 | 255.36 | 250 | 447.02 |
Selling, General & Admin | 151 | 141.32 | 145.52 | 145.13 | 139.3 | 141.4 |
Research & Development | 41.01 | 39.51 | 39.54 | 36.18 | 36.69 | 42.08 |
Other Operating Expenses | 5.57 | 5.05 | 4.06 | 3.41 | 6.14 | 8.82 |
Operating Expenses | 199.03 | 187.35 | 189.58 | 183.67 | 183.7 | 194.68 |
Operating Income | 31.8 | 50.11 | 33.18 | 71.68 | 66.3 | 252.34 |
Interest Expense | -1.74 | -1.35 | -0.25 | -0.44 | -0.6 | -4.83 |
Interest & Investment Income | 8.42 | 8.97 | 22.05 | 48.2 | 14.89 | 3.74 |
Currency Exchange Gain (Loss) | 1.87 | 1.87 | -2.81 | 1.95 | 1.4 | 0.72 |
Other Non Operating Income (Expenses) | -4.03 | -0.42 | -0.58 | -0.42 | -0.27 | -1.31 |
EBT Excluding Unusual Items | 36.33 | 59.17 | 51.58 | 120.97 | 81.72 | 250.66 |
Gain (Loss) on Sale of Investments | 7.81 | 8.38 | 5.85 | 3.26 | 25.83 | - |
Gain (Loss) on Sale of Assets | -0.14 | -0.54 | 0 | 0.21 | 0.27 | -0.02 |
Asset Writedown | 0.42 | -0.03 | -0.05 | -0.04 | -0.84 | - |
Other Unusual Items | 3.61 | 2.15 | 1.17 | 12.87 | 0.35 | 2.38 |
Pretax Income | 48.02 | 69.13 | 58.55 | 137.27 | 107.33 | 253.02 |
Income Tax Expense | 6.24 | 9.27 | 8.98 | 19.34 | 13.58 | 37 |
Earnings From Continuing Operations | 41.79 | 59.86 | 49.57 | 117.93 | 93.75 | 216.02 |
Minority Interest in Earnings | 0.62 | 0.31 | 0 | - | - | - |
Net Income | 42.41 | 60.18 | 49.57 | 117.93 | 93.75 | 216.02 |
Net Income to Common | 42.41 | 60.18 | 49.57 | 117.93 | 93.75 | 216.02 |
Net Income Growth | -25.96% | 21.39% | -57.96% | 25.79% | -56.60% | 165.52% |
Shares Outstanding (Basic) | 161 | 164 | 166 | 175 | 175 | 139 |
Shares Outstanding (Diluted) | 161 | 164 | 166 | 177 | 175 | 139 |
Shares Change (YoY) | -2.44% | -1.44% | -5.92% | 0.98% | 26.34% | 5.62% |
EPS (Basic) | 0.26 | 0.37 | 0.30 | 0.67 | 0.54 | 1.56 |
EPS (Diluted) | 0.26 | 0.37 | 0.30 | 0.67 | 0.54 | 1.56 |
EPS Growth | -24.11% | 23.15% | -55.32% | 24.56% | -65.65% | 151.39% |
Free Cash Flow | -8.12 | -17.09 | -14.65 | -73.39 | -78.73 | 92.78 |
Free Cash Flow Per Share | -0.05 | -0.10 | -0.09 | -0.41 | -0.45 | 0.67 |
Dividend Per Share | 0.050 | 0.050 | 0.200 | 0.462 | 0.231 | 0.538 |
Dividend Growth | -75.00% | -75.00% | -56.66% | 99.70% | -57.08% | - |
Gross Margin | 38.25% | 38.33% | 37.99% | 40.99% | 42.80% | 54.46% |
Operating Margin | 5.27% | 8.09% | 5.66% | 11.51% | 11.35% | 30.74% |
Profit Margin | 7.03% | 9.71% | 8.45% | 18.93% | 16.05% | 26.32% |
Free Cash Flow Margin | -1.35% | -2.76% | -2.50% | -11.78% | -13.48% | 11.30% |
EBITDA | 100.86 | 116.55 | 89.15 | 116.13 | 101.15 | 280.45 |
EBITDA Margin | 16.71% | 18.82% | 15.20% | 18.64% | 17.32% | 34.16% |
D&A For EBITDA | 69.06 | 66.45 | 55.98 | 44.45 | 34.84 | 28.11 |
EBIT | 31.8 | 50.11 | 33.18 | 71.68 | 66.3 | 252.34 |
EBIT Margin | 5.27% | 8.09% | 5.66% | 11.51% | 11.35% | 30.74% |
Effective Tax Rate | 12.99% | 13.41% | 15.33% | 14.09% | 12.65% | 14.62% |
Revenue as Reported | 603.43 | 619.45 | 586.41 | 622.92 | 584.14 | 820.87 |
Advertising Expenses | - | 0.53 | 0.53 | 1.07 | 2.57 | 1.69 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.